ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0244

Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab

Yicong Li1, Chun Wu2, Michael Maldonado2, Peter Schafer2, S. Louis Bridges, Jr.3, William Rigby4, Vivian Bykerk3, Jane Buckner5 and Jinqi Liu2, 1Parexel International, Durham, NC, 2Bristol Myers Squibb, Princeton, NJ, 3Hospital for Special Surgery, New York, NY, 4Dartmouth Hitchcock Medical Center, Lebanon, PA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Cardiovascular, prognostic factors, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular (CV) disease.1 Although novel DMARD therapies effectively control RA disease activity, the impact on CV risk appears variable.2 Identifying validated predictive response biomarkers (BM) associated with existing therapies would advance clinical decision making and guide development for precision medicine approaches. This exploratory analysis assessed the utility of serum CV BM for predicting clinical response in patients with RA from the Early AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE RA subjects with background MTX) study.3

Methods: Early AMPLE (NCT02557100) was a phase 4 head-to-head comparison of treatment response to either abatacept or adalimumab in patients with early RA with an inadequate response to MTX and dual seropositivity for RF and high ACPA titers, predicted to favor response to abatacept.3 Data for this analysis were generated by the Olink Target 96 multiplex immunoassay platform CV II/III panels (with proximity extension assay), using serum samples collected at baseline (BL) and week 24 for both treatments. Disease activity was monitored using high sensitivity-CRP, tender and swollen joint count, DAS28 (CRP), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index. Relationships between CV BM and disease activity were examined via Spearman’s correlations. The prediction model included age, ACPA positivity, BL disease activity, and shared epitope as covariates.

Results: Among all patients, IL-2 receptor α (IL2RA) was the only CV BM (out of 179 analyzed) that positively correlated with all disease activity measures at BL (Spearman’s ρ = 0.24–0.58). Change from BL in IL2RA and E-selectin positively correlated with improvement in disease activity at week 24 (all patients; ρ = 0.27-0.39 and 0.31-0.45, respectively). BL levels of 3 CV BM, angiopoietin-1 (ANGPT1), TNF receptor superfamily member 10C (TNFRSF10C), and gastric intrinsic factor (GIF) showed opposite patterns of association with treatment response for abatacept vs adalimumab (Figure 1). Low BL levels of TNFRSF10C and high BL levels of ANGPT1 and GIF indicated a higher likelihood of achieving DAS28 (CRP) < 2.6 in patients treated with abatacept (Figure 2). High levels of ANGPT1 (odds ratio [OR] 2.13 [95% confidence interval (CI) 0.47–3.78]) and GIF (1.93 [0.27–3.60]) and low levels of TNFRSF10C (1.89 [0.14–3.64]) correlated with a higher likelihood of achieving SDAI remission for patients treated with abatacept.

Conclusion: Only 1 CV BM correlated with BL RA disease activity, while 3 CV BM (ANGPT1, TNFRSF10C, and GIF) were identified as potential BM for predicting clinical response by treatment arm. These results uncover novel links between CV BM and RA differential response to abatacept and adalimumab, providing new avenues toward continued investigation of precision medicine approaches.
1England BR, et al. BMJ 2018;361:k1036.
2Santos-Moreno P, et al. RMD Open 2021;7:e001470.
3Rigby W, et al. Arthritis Res Ther 2021;23:245.

Medical writing: Ryan Miller (Caudex), funded by Bristol Myers Squibb.

Supporting image 1

Supporting image 2


Disclosures: Y. Li, None; C. Wu, Bristol Myers Squibb; M. Maldonado, Bristol Myers Squibb; P. Schafer, Bristol Myers Squibb; S. Bridges, Jr., Bristol Myers Squibb; W. Rigby, Bristol Myers Squibb, AbbVie; V. Bykerk, Janssen, Bristol Myers Squibb, Crossbridge, Pfizer, Sanofi Aventis, Brainstorm Therapeutics, Amgen, UCB, Gilead, Genzyme Corporation, Regeneron; J. Buckner, Amgen, Bristol Myers Squibb, Gentiobio, Hot Spot Therapeutics, Janssen, Pfizer, Novo Nordisk, Allen Institute for Immunology, Type 1 Diabetes TrialNet Study Group, La Jolla Institute, Oklahoma Medical Research Foundation, Bristol Myers Squibb Immunology, Colton Center for Autoimmunity at Penn, Board of Scientific Counsellors; J. Liu, Bristol Myers Squibb.

To cite this abstract in AMA style:

Li Y, Wu C, Maldonado M, Schafer P, Bridges, Jr. S, Rigby W, Bykerk V, Buckner J, Liu J. Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identification-of-novel-response-predictors-via-cardiovascular-biomarker-proteomic-analysis-of-serum-samples-from-patients-with-early-seropositive-ra-treated-with-abatacept-or-adalimumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-novel-response-predictors-via-cardiovascular-biomarker-proteomic-analysis-of-serum-samples-from-patients-with-early-seropositive-ra-treated-with-abatacept-or-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology